Login / Signup

Ryanodine receptor stabilization therapy suppresses Ca 2+ - based arrhythmias in a novel model of metabolic HFpEF.

Aaron D KaplanLiron BoymanChristopher W WardW Jonathan LedererMaura Greiser
Published in: Journal of molecular and cellular cardiology (2024)
Heart Failure with preserved ejection fraction (HFpEF) has a high rate of sudden cardiac death (SCD) and empirical treatment is ineffective. We developed a novel preclinical model of metabolic HFpEF that presents with stress-induced ventricular tachycardia (VT). Mechanistically, we discovered arrhythmogenic changes in intracellular Ca 2+ handling distinct from the changes pathognomonic for heart failure with reduced ejection fraction. We further show that dantrolene, a stabilizer of the ryanodine receptor Ca 2+ channel, attenuates HFpEF-associated arrhythmogenic Ca 2+ handling in vitro and suppresses stress-induced VT in vivo. We propose ryanodine receptor stabilization as a mechanistic approach to mitigation of malignant VT in metabolic HFpEF.
Keyphrases
  • stress induced
  • heart failure
  • protein kinase
  • signaling pathway
  • climate change
  • stem cells
  • binding protein
  • atrial fibrillation
  • reactive oxygen species
  • cardiac resynchronization therapy
  • acute heart failure